{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:49:58Z","timestamp":1793054998599,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ketogenic diet (KD) is increasingly used to treat drug-resistant epilepsy because of its favorable effect on seizure reduction. Patients with mitochondrial diseases tend to experience seizures. Therefore, this study aimed to test the efficacy of the KD on participants with mitochondrial diseases in a controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants from fourteen clinical centers who were diagnosed with mitochondrial disease were semi-randomized to either the intervention (KD) or control group. The KD group followed a 3-month KD intervention, while the control group received a 1-month normal diet initially and then a 3-month KD intervention. The primary outcome measure was seizure reduction. Biomarker changes, cognitive impairments, and side effects were also recorded, if available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      A total of 33 participants were assigned to the KD (\n                      <jats:italic>n<\/jats:italic>\n                      = 22) and control groups (\n                      <jats:italic>n<\/jats:italic>\n                      = 11). In the KD group, 31.8% (7\/22) of participants achieved \u226550% seizure reduction after 1 month of diet intervention, which increased to 40.9% (9\/22) at 3 months. In the control group, only 18.2% (2\/11) of the participants had \u226550% seizure reduction during the normal diet period. After the control group was transferred to the KD, 63.6% (7\/11) of participants had &amp;gt;50% seizure reduction, and this rate increased to 72.7% (8\/11) at 3 months. The KD also showed high efficacy in participants with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) or pathogenic variants in mitochondrial DNA (mtDNA) (90% and 93.3% response rates, respectively). The most frequent side effects reported at the 3-month review were vomiting, cold, hyperlipidemia, and bloating.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The KD is a safe and effective therapy for seizure control in mitochondrial diseases, especially MELAS and pathogenic variants of mtDNA. KD intervention can be considered in the management of these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.880944","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:33:20Z","timestamp":1659339200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and Safety of the Ketogenic Diet for Mitochondrial Disease With Epilepsy: A Prospective, Open-labeled, Controlled Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lijuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1528-1167.2008.01783.x","article-title":"Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies","volume":"39","author":"Khurana","year":"2008","journal-title":"Epilepsia."},{"key":"B2","first-page":"796","article-title":"Neuromuscular Disorders Of Infancy, Childhood, And Adolescence","volume-title":"Mitochondrial Encephalomyopathies","author":"De Vivo","year":"2015"},{"key":"B3","first-page":"41","article-title":"Mechanisms of mitochondrial diseases","volume-title":"Annals Med","author":"Ylikallio","year":"2012"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ceca.2016.03.003","article-title":"Mitochondrial cytopathies","volume":"60","author":"El-Hattab","year":"2016","journal-title":"CellCalcium."},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biocel.2015.01.022","article-title":"Mitochondria: the ketogenic diet\u2014a metabolism-based therapy","volume":"63","author":"Vidali","year":"2015","journal-title":"Int J Biochem Cell Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.braindev.2013.01.006","article-title":"Mitochondrial disease and epilepsy","volume":"35","author":"Hoon-Chul","year":"2013","journal-title":"Brain Dev."},{"key":"B7","article-title":"Primary Mitochondrial Disorders Overview","volume-title":"GeneReviews","author":"Chinnery","year":"2000"},{"key":"B8","unstructured":"433Valproate.2012"},{"key":"B9","first-page":"100342","article-title":"Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation","volume-title":"Epilepsy Behav Rep Oct","author":"Bassett","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5114\/fn.2021.104542","article-title":"Valproic acid for myoclonic epilepsy in POLG1 carriers can be fatal","volume":"59","author":"Finsterer","year":"2021","journal-title":"Folia Neuropathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1091581817721675","article-title":"Drug-induced liver injury in children: clinical observations, animal models, regulatory status","volume":"36","author":"Shi","year":"2017","journal-title":"Int J Toxicol"},{"key":"B12","first-page":"33","volume-title":"Clinical Diagnosis and Treatment Guidelines, Epilepsy Volume (in Chinese)","year":"2015"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/WCO.0000000000000432","article-title":"New insights into the mechanisms of the ketogenic diet","volume":"30","author":"Boison","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00676","article-title":"Front Pharmacology","volume":"8","author":"Chiara","year":"2017"},{"key":"B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/ph15050495","article-title":"Anti-seizure effects of cannabidiol leading to increased peroxisome proliferator-activated receptor gamma levels in the hippocampal CA3 subfield of epileptic rats","volume":"15","author":"Costa","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u00df-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 Involvement","volume":"6","author":"Giuseppe","year":"2011","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1528-1167.2007.01522.x","article-title":"Mitochondrial respiratory chain defects: Underlying etiology in various epileptic conditions","volume":"49","author":"Lee","year":"2008","journal-title":"Epilepsia."},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1528-1167.2006.00906.x","article-title":"Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects","volume":"48","author":"Hoon-Chul","year":"2007","journal-title":"Epilepsia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1469-8749.2009.03541.x","article-title":"Pyruvate dehydrogenase complex deficiency: Four neurological phenotypes with differing pathogenesis","volume":"52","author":"Barnerias","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1684\/epd.2012.0543","article-title":"Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet","volume":"14","author":"Martikainen","year":"2012","journal-title":"Epileptic Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.braindev.2008.12.020","article-title":"case of Ohtahara syndrome with mitochondrial respiratory chain complex I deficiency","volume":"32","author":"Seo","year":"2010","journal-title":"Brain Dev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"B23","first-page":"16","article-title":"Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety","volume-title":"Orphanet J Rare Dis","author":"Zweers","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/ane.12137","article-title":"Modified Atkins diet vs classic ketogenic formula in intractable epilepsy","volume":"128","author":"El-Rashidy","year":"2013","journal-title":"Acta Neurol Scand."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/epi.14457","article-title":"Effect of modified Atkins diet in adults with drug-resistant focal epilepsy: a randomized clinical trial","volume":"59","author":"Magnhild","year":"2018","journal-title":"Epilepsia"},{"key":"B26","unstructured":"A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurologica Scandinavica.2319\n            LambrechtsDAJE\n            KinderenRJA\n            VlesJSHA\n            LouwJA\n            AldenkampAP\n            HJM\n          10.1111\/ane.12592270278471352017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1474-4422(08)70092-9","article-title":"The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial","volume":"7","author":"Neal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/epi.12069","article-title":"Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial","volume":"54","author":"Sharma","year":"2013","journal-title":"Epilepsia;."},{"key":"B29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eplepsyres.2016.09.002","article-title":"Evaluation of a simplified modified Atkins diet for use by parents with low levels of literacy in children with refractory epilepsy: a randomized controlled trial","volume":"127","author":"Sharma","year":"2016","journal-title":"Epilepsy Res"},{"key":"B30","first-page":"72","article-title":"Modified Atkins diet in adult with refractory epilepsy: a controlled randomized clinical trial","volume":"16","author":"Zare","year":"2017","journal-title":"Iran J Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD001903","DOI":"10.1002\/14651858.CD001903.pub4","article-title":"Ketogenic diets for drug-resistant epilepsy","volume":"11","author":"Martin-Mcgill","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/epi4.12225","article-title":"Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group","volume":"21","author":"Eric Kossoff","year":"2018","journal-title":"Epilepsia Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1528-1167.2007.01025.x","article-title":"Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios -comparison of 3:1 with 4:1 diet","volume":"48","author":"Seo","year":"2007","journal-title":"Epilepsia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eplepsyres.2011.05.005","article-title":"Efficacy of 4:1 (classic) versus 25:1 ketogenic ratio diets in refractory epilepsy in young children: a randomized open labeled study","volume":"96","author":"Raju","year":"2011","journal-title":"Epilepsy Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ajmg.1320250525","volume":"1","author":"Haas","year":"1986","journal-title":"Am J Med Genet Suppl"},{"key":"B36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3760\/cma.j.issn.1003-9406.2018.04.020","article-title":"Analysis of a female neonate with pyruvate dehydrogenase complex deficiency","volume":"10","author":"Zhang","year":"2018","journal-title":"Chin J Med Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yebeh.2018.06.004","article-title":"Cognitive benefits of the ketogenic diet in patients with epilepsy: a systematic overview","volume":"87","author":"Van Berkel","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.20344\/amp.12184","article-title":"Ketogenic diet for refractory childhood epilepsy: beyond seizures control, the experience of a portuguese pediatric centre","volume":"2","author":"Luz","year":"2019","journal-title":"Acta Med Port"},{"key":"B39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ana.410310408","article-title":"MELAS: clinical features, biochemistry, molecular genetics","volume":"31","author":"Ciafaloni","year":"1992","journal-title":"Ann Neurol"},{"key":"B40","first-page":"651","article-title":"A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies","volume-title":"Nature","author":"Goto","year":"1990"},{"key":"B41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41439-018-0026-6","article-title":"Mitochondrial DNA 3243A>T mutation in a patient with MELAS syndrome","volume":"5","author":"Ikeda","year":"2018","journal-title":"Hum Genome Var"},{"key":"B42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/chd.12634","article-title":"Mitochondrial DNA mutation \u201cm","volume":"13","author":"Niedermayr","year":"2018","journal-title":"Congenit Heart Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/jmg.2004.020537","article-title":"Mutations of the mitochondrial ND1 gene as a cause of MELAS","volume":"41","author":"Kirby","year":"2004","journal-title":"J Med Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00415-016-8086-3","article-title":"Expanded phenotypic spectrum of the m.8344A>G \u201cMERRF\u201d mutation: data from the German mitoNET registry","volume":"263","author":"Altmann","year":"2016","journal-title":"J Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2329048X21991382","article-title":"Leigh Syndrome as a Phenotype of Near-Homoplasmic m.8344 A>G Variant in Children","volume":"2","author":"Russo","year":"2021","journal-title":"Child Neurol Open"},{"key":"B46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.bbadis.2016.10.028","article-title":"The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model","volume":"1863","author":"Frey","year":"2017","journal-title":"Biochimica Et Biophysica Acta (BBA)-Molecular Basis Of Disease."},{"key":"B47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.pediatrneurol.2014.01.009","article-title":"Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet","volume":"50","author":"Steriade","year":"2014","journal-title":"Pediatr Neurol;."},{"key":"B48","first-page":"9","article-title":"Quantitative variation in m.3243A>G mutation produce discrete changes in energy metabolism","volume-title":"Sci Rep","author":"Mcmillan","year":"2019"},{"key":"B49","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/00008877-200609000-00009","volume":"17","author":"Gasior","year":"2006","journal-title":"Behav Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.20899","article-title":"Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet","volume":"60","author":"Bough","year":"2006","journal-title":"Ann Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"650624","DOI":"10.3389\/fped.2021.650624","article-title":"Ketogenic Diet and the Treatment of Autism Spectrum Disorder","volume":"9","author":"Li","year":"2021","journal-title":"Front Pediat."},{"key":"B52","doi-asserted-by":"publisher","first-page":"107181","DOI":"10.1016\/j.yebeh.2020.107181","article-title":"Ketogenic diet therapy provision in the COVID-19 pandemic: Dual-center experience and recommendations","volume":"111","author":"Kossoff","year":"2020","journal-title":"Epilepsy Behavior E&B."},{"key":"B53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.seizure.2021.10.021","volume":"94","author":"Yang","year":"2021","journal-title":"Seizure"},{"key":"B54","doi-asserted-by":"publisher","first-page":"CD001903","DOI":"10.1002\/14651858.CD001903.pub2","article-title":"Ketogenic diet and other dietary treatments for epilepsy","volume":"3","author":"Levy","year":"2012","journal-title":"Cochrane Database Syst Rev;."},{"key":"B55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnut.2019.00112","volume":"6","author":"Marchi\u00f2","year":"2019","journal-title":"Front Nutr"},{"key":"B56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/epi.13256","article-title":"Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy","volume":"57","author":"Kim","year":"2015","journal-title":"Epilepsia."},{"key":"B57","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12519-017-0053-2","article-title":"Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies","volume":"13","author":"Cai","year":"2017","journal-title":"World J Pediatr"},{"key":"B58","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jama.290.7.912","article-title":"Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children","volume":"290","author":"Jr","year":"2003","journal-title":"JAMA."},{"key":"B59","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1017\/S0012162206002143","article-title":"Long-term use of the ketogenic diet in the treatment of epilepsy","volume":"48","author":"Groesbeck","year":"2006","journal-title":"Dev Med Child Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.880944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:33:32Z","timestamp":1659339212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.880944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":59,"alternative-id":["10.3389\/fneur.2022.880944"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.880944","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"880944"}}